The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic

Matthew S. Gentry, Zaid Afawi, Dustin D. Armstrong, Antonio Delgado-Escueta, Y. Paul Goldberg, Tamar R. Grossman, Joan J. Guinovart, Frank Harris, Thomas D. Hurley, Roberto Michelucci, Berge A. Minassian, Pascual Sanz, Carolyn A. Worby, Jose M. Serratosa

Research output: Contribution to journalArticle

Abstract

Lafora disease (LD) is both a fatal childhood epilepsy and a glycogen storage disease caused by recessive mutations in either the Epilepsy progressive myoclonus 2A (EPM2A) or EPM2B genes. Hallmarks of LD are aberrant, cytoplasmic carbohydrate aggregates called Lafora bodies (LBs) that are a disease driver. The 5th International Lafora Epilepsy Workshop was recently held in Alcala de Henares, Spain. The workshop brought together nearly 100 clinicians, academic and industry scientists, trainees, National Institutes of Health (NIH) representation, and friends and family members of patients with LD. The workshop covered aspects of LD ranging from defining basic scientific mechanisms to elucidating a LD therapy or cure and a recently launched LD natural history study.

Original languageEnglish (US)
Article number106839
JournalEpilepsy and Behavior
Volume103
DOIs
StatePublished - Feb 2020

Fingerprint

Lafora Disease
Epilepsy
Education
Therapeutics
Progressive Myoclonic Epilepsy
Glycogen Storage Disease
National Institutes of Health (U.S.)
Natural History
Spain
Industry
Carbohydrates
Mutation

Keywords

  • Glycogen
  • Glycogen storage disease
  • Lafora disease
  • Neurodegeneration
  • Progressive myoclonus epilepsy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Gentry, M. S., Afawi, Z., Armstrong, D. D., Delgado-Escueta, A., Goldberg, Y. P., Grossman, T. R., ... Serratosa, J. M. (2020). The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic. Epilepsy and Behavior, 103, [106839]. https://doi.org/10.1016/j.yebeh.2019.106839

The 5th International Lafora Epilepsy Workshop : Basic science elucidating therapeutic options and preparing for therapies in the clinic. / Gentry, Matthew S.; Afawi, Zaid; Armstrong, Dustin D.; Delgado-Escueta, Antonio; Goldberg, Y. Paul; Grossman, Tamar R.; Guinovart, Joan J.; Harris, Frank; Hurley, Thomas D.; Michelucci, Roberto; Minassian, Berge A.; Sanz, Pascual; Worby, Carolyn A.; Serratosa, Jose M.

In: Epilepsy and Behavior, Vol. 103, 106839, 02.2020.

Research output: Contribution to journalArticle

Gentry, MS, Afawi, Z, Armstrong, DD, Delgado-Escueta, A, Goldberg, YP, Grossman, TR, Guinovart, JJ, Harris, F, Hurley, TD, Michelucci, R, Minassian, BA, Sanz, P, Worby, CA & Serratosa, JM 2020, 'The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic', Epilepsy and Behavior, vol. 103, 106839. https://doi.org/10.1016/j.yebeh.2019.106839
Gentry, Matthew S. ; Afawi, Zaid ; Armstrong, Dustin D. ; Delgado-Escueta, Antonio ; Goldberg, Y. Paul ; Grossman, Tamar R. ; Guinovart, Joan J. ; Harris, Frank ; Hurley, Thomas D. ; Michelucci, Roberto ; Minassian, Berge A. ; Sanz, Pascual ; Worby, Carolyn A. ; Serratosa, Jose M. / The 5th International Lafora Epilepsy Workshop : Basic science elucidating therapeutic options and preparing for therapies in the clinic. In: Epilepsy and Behavior. 2020 ; Vol. 103.
@article{d8f98661408743b9899b7d168c93c78e,
title = "The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic",
abstract = "Lafora disease (LD) is both a fatal childhood epilepsy and a glycogen storage disease caused by recessive mutations in either the Epilepsy progressive myoclonus 2A (EPM2A) or EPM2B genes. Hallmarks of LD are aberrant, cytoplasmic carbohydrate aggregates called Lafora bodies (LBs) that are a disease driver. The 5th International Lafora Epilepsy Workshop was recently held in Alcala de Henares, Spain. The workshop brought together nearly 100 clinicians, academic and industry scientists, trainees, National Institutes of Health (NIH) representation, and friends and family members of patients with LD. The workshop covered aspects of LD ranging from defining basic scientific mechanisms to elucidating a LD therapy or cure and a recently launched LD natural history study.",
keywords = "Glycogen, Glycogen storage disease, Lafora disease, Neurodegeneration, Progressive myoclonus epilepsy",
author = "Gentry, {Matthew S.} and Zaid Afawi and Armstrong, {Dustin D.} and Antonio Delgado-Escueta and Goldberg, {Y. Paul} and Grossman, {Tamar R.} and Guinovart, {Joan J.} and Frank Harris and Hurley, {Thomas D.} and Roberto Michelucci and Minassian, {Berge A.} and Pascual Sanz and Worby, {Carolyn A.} and Serratosa, {Jose M.}",
year = "2020",
month = "2",
doi = "10.1016/j.yebeh.2019.106839",
language = "English (US)",
volume = "103",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The 5th International Lafora Epilepsy Workshop

T2 - Basic science elucidating therapeutic options and preparing for therapies in the clinic

AU - Gentry, Matthew S.

AU - Afawi, Zaid

AU - Armstrong, Dustin D.

AU - Delgado-Escueta, Antonio

AU - Goldberg, Y. Paul

AU - Grossman, Tamar R.

AU - Guinovart, Joan J.

AU - Harris, Frank

AU - Hurley, Thomas D.

AU - Michelucci, Roberto

AU - Minassian, Berge A.

AU - Sanz, Pascual

AU - Worby, Carolyn A.

AU - Serratosa, Jose M.

PY - 2020/2

Y1 - 2020/2

N2 - Lafora disease (LD) is both a fatal childhood epilepsy and a glycogen storage disease caused by recessive mutations in either the Epilepsy progressive myoclonus 2A (EPM2A) or EPM2B genes. Hallmarks of LD are aberrant, cytoplasmic carbohydrate aggregates called Lafora bodies (LBs) that are a disease driver. The 5th International Lafora Epilepsy Workshop was recently held in Alcala de Henares, Spain. The workshop brought together nearly 100 clinicians, academic and industry scientists, trainees, National Institutes of Health (NIH) representation, and friends and family members of patients with LD. The workshop covered aspects of LD ranging from defining basic scientific mechanisms to elucidating a LD therapy or cure and a recently launched LD natural history study.

AB - Lafora disease (LD) is both a fatal childhood epilepsy and a glycogen storage disease caused by recessive mutations in either the Epilepsy progressive myoclonus 2A (EPM2A) or EPM2B genes. Hallmarks of LD are aberrant, cytoplasmic carbohydrate aggregates called Lafora bodies (LBs) that are a disease driver. The 5th International Lafora Epilepsy Workshop was recently held in Alcala de Henares, Spain. The workshop brought together nearly 100 clinicians, academic and industry scientists, trainees, National Institutes of Health (NIH) representation, and friends and family members of patients with LD. The workshop covered aspects of LD ranging from defining basic scientific mechanisms to elucidating a LD therapy or cure and a recently launched LD natural history study.

KW - Glycogen

KW - Glycogen storage disease

KW - Lafora disease

KW - Neurodegeneration

KW - Progressive myoclonus epilepsy

UR - http://www.scopus.com/inward/record.url?scp=85077677812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077677812&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2019.106839

DO - 10.1016/j.yebeh.2019.106839

M3 - Article

C2 - 31932179

AN - SCOPUS:85077677812

VL - 103

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

M1 - 106839

ER -